$TRDA
Entrada Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000168937524000063 Filed on November 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $19.57M
YoY Change -55.25%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.971M
YoY Change 32.42%
% of Gross Profit
Research & Development $31.26M
YoY Change 40.85%
% of Gross Profit
Depreciation & Amortization $900.0K
YoY Change 12.5%
% of Gross Profit
Operating Expenses $41.23M
YoY Change 38.71%
Operating Profit -$21.66M
YoY Change -254.57%
Interest Expense $5.766M
YoY Change 42.37%
% of Operating Profit
Other Income/Expense, Net $5.766M
YoY Change 42.34%
Pretax Income -$15.89M
YoY Change -188.0%
Income Tax -$1.900M
% Of Pretax Income
Net Earnings -$14.03M
YoY Change -139.57%
Net Earnings / Revenue -71.7%
Basic Earnings Per Share -$0.35
Diluted Earnings Per Share -$0.35
COMMON SHARES
Basic Shares Outstanding 37.42M shares 37.20M shares
Diluted Shares Outstanding 40.63M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $449.3M
YoY Change 27.08%
Cash & Equivalents $78.05M
Short-Term Investments $371.3M
Other Short-Term Assets $13.39M
YoY Change -45.13%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $465.3M
YoY Change 21.48%
LONG-TERM ASSETS
Property, Plant & Equipment $10.79M
YoY Change -2.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $746.0K
YoY Change -74.97%
Total Long-Term Assets $89.26M
YoY Change -12.49%
TOTAL ASSETS
Total Short-Term Assets $465.3M
Total Long-Term Assets $89.26M
Total Assets $554.6M
YoY Change 14.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.292M
YoY Change 71.81%
Accrued Expenses $13.40M
YoY Change 39.63%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $70.60M
YoY Change -57.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $61.54M
YoY Change -15.58%
Total Long-Term Liabilities $61.54M
YoY Change -15.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $70.60M
Total Long-Term Liabilities $61.54M
Total Liabilities $132.1M
YoY Change -44.56%
SHAREHOLDERS EQUITY
Retained Earnings -$130.5M
YoY Change -29.61%
Common Stock $4.000K
YoY Change 33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $422.4M
YoY Change
Total Liabilities & Shareholders Equity $554.6M
YoY Change 14.34%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$14.03M
YoY Change -139.57%
Depreciation, Depletion And Amortization $900.0K
YoY Change 12.5%
Cash From Operating Activities -$24.27M
YoY Change -0.96%
INVESTING ACTIVITIES
Capital Expenditures $639.0K
YoY Change -54.36%
Acquisitions
YoY Change
Other Investing Activities -$82.29M
YoY Change 3477.74%
Cash From Investing Activities -$82.93M
YoY Change 2141.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -11.00K
YoY Change -103.67%
NET CHANGE
Cash From Operating Activities -24.27M
Cash From Investing Activities -82.93M
Cash From Financing Activities -11.00K
Net Change In Cash -107.2M
YoY Change 284.24%
FREE CASH FLOW
Cash From Operating Activities -$24.27M
Capital Expenditures $639.0K
Free Cash Flow -$24.91M
YoY Change -3.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001689375
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 17-500
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02210
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
520-9158
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
TRDA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
284367000 usd
CY2024Q3 us-gaap Contract With Customer Receivable After Allowance For Credit Loss
ContractWithCustomerReceivableAfterAllowanceForCreditLoss
2603000 usd
CY2023Q4 us-gaap Contract With Customer Receivable After Allowance For Credit Loss
ContractWithCustomerReceivableAfterAllowanceForCreditLoss
5878000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13388000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11924000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
465335000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
369771000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10786000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11191000 usd
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3950000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3950000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
746000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2790000 usd
CY2024Q3 us-gaap Assets
Assets
554590000 usd
CY2023Q4 us-gaap Assets
Assets
469192000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1292000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3277000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13403000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11325000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7738000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7909000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
158796000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
53576000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
60321000 usd
CY2024Q3 us-gaap Deferred Revenue
DeferredRevenue
7964000 usd
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
7715000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
132143000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
226832000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37414899 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33461771 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33437296 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
4000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
551946000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
437132000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
972000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
195000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-130475000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-194970000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
422447000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
71593000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21658000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28606000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23639000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
52878000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-8067000 usd
CY2023Q3 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
18063000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-17398000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2729000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-14032000 usd
us-gaap Net Income Loss
NetIncomeLoss
64495000 usd
us-gaap Net Income Loss
NetIncomeLoss
2859000 usd
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1301000 usd
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
509000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
777000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1561000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1301000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
509000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
777000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1561000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
35970000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
65272000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4420000 usd
CY2023Q1 trda Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
26000 usd
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
67224000 usd
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
2859000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32942958 shares
dei Entity File Number
EntityFileNumber
001-40969
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67602000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
371295000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
73773000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
81490000 usd
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37400499 shares
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19570000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31257000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9971000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
35461000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.07
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.02
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12731000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
41228000 usd
CY2024Q3 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-15892000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1860000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40629602 shares
CY2024Q3 trda Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
5766000 usd
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37419975 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
78049000 usd
CY2024Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
2251000 usd
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
4024000 usd
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
45919000 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
132261000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
70603000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
554590000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
469192000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
43735000 usd
dei Document Transition Report
DocumentTransitionReport
false
us-gaap Operating Expenses
OperatingExpenses
120506000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
dei Entity Address Address Line1
EntityAddressAddressLine1
One Design Center Place
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
242360000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
173384000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36118930 shares
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19407000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2755000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1415000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6674000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
206908000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
242360000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
206000 usd
CY2024Q1 trda Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
13000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
29723000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.72
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
129000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22191000 usd
us-gaap Operating Expenses
OperatingExpenses
95232000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
14012000 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37583486 shares
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
229612000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
257000 usd
CY2023Q2 trda Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
25000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
186000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent
CY2024Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent
dei Entity Registrant Name
EntityRegistrantName
ENTRADA THERAPEUTICS, INC.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3983399
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
87165000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
91900000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7532000 usd
CY2023Q3 trda Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
4051000 usd
trda Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
14346000 usd
trda Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
10926000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5766000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4051000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14346000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10926000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33281287 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40629602 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34775451 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37583486 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34289411 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
212554000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
229612000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
257000 usd
CY2023Q2 trda Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
25000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
186000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3119000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-363000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-25928000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
368000 usd
CY2023Q3 trda Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
21000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3396000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
509000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
35461000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
246663000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3733000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-441000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
23496000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
269367000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1104000 usd
CY2024Q2 trda Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
13000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
263000 usd
CY2024Q2 trda Common Stock Issuance Cost
CommonStockIssuanceCost
392000 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
99608000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4622000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-83000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
55031000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
429925000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
381000 usd
CY2024Q3 trda Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
12000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4860000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1301000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-14032000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
422447000 usd
us-gaap Profit Loss
ProfitLoss
64495000 usd
us-gaap Profit Loss
ProfitLoss
2859000 usd
us-gaap Depreciation
Depreciation
2781000 usd
us-gaap Depreciation
Depreciation
2105000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
13215000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
9270000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
7511000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3780000 usd
us-gaap Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
-3275000 usd
us-gaap Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
5025000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1464000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3894000 usd
trda Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-7717000 usd
trda Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-11146000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-2044000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
11754000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1855000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-5211000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2133000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1857000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-1773000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
0 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-6916000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-12703000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-86093000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
158946000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9952000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
143816000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2523000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4638000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
373220000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
318686000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
294580000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
165886000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3119000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-363000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-25928000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-81163000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-157438000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1691000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
754000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
263000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
186000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
101562000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20347000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10447000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6725000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71552000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49107000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81999000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55832000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
60000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
299000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
77584000 usd
trda Right Of Use Asset Surrendered As Part Of Lease Modification
RightOfUseAssetSurrenderedAsPartOfLeaseModification
0 usd
trda Right Of Use Asset Surrendered As Part Of Lease Modification
RightOfUseAssetSurrenderedAsPartOfLeaseModification
7761000 usd
trda Transfer Of Deposits For Equipment From Operating To Investing Cash Flows
TransferOfDepositsForEquipmentFromOperatingToInvestingCashFlows
0 usd
trda Transfer Of Deposits For Equipment From Operating To Investing Cash Flows
TransferOfDepositsForEquipmentFromOperatingToInvestingCashFlows
617000 usd
trda Vesting Of Options Early Exercised Subject To Repurchase
VestingOfOptionsEarlyExercisedSubjectToRepurchase
38000 usd
trda Vesting Of Options Early Exercised Subject To Repurchase
VestingOfOptionsEarlyExercisedSubjectToRepurchase
72000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-130500000 usd
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
449300000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
78049000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67602000 usd
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3950000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3950000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81999000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71552000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
370323000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
980000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
8000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
371295000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
284172000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
265000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
70000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
284367000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
2 security
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
8800000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest
DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest
0 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
1200000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
1700000 usd
CY2023Q4 us-gaap Cash
Cash
500000 usd
CY2024Q3 us-gaap Cash
Cash
500000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19253000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17114000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8467000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5923000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10786000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11191000 usd
CY2024Q3 us-gaap Depreciation
Depreciation
900000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
800000 usd
us-gaap Depreciation
Depreciation
2800000 usd
us-gaap Depreciation
Depreciation
2100000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6581000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6660000 usd
CY2024Q3 trda Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
5110000 usd
CY2023Q4 trda Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
2894000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
737000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
767000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
975000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1004000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13403000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11325000 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10306668 shares
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9220192 shares
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4860000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3396000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13215000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9270000 usd
trda Stock Issued During Period Shares Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions
4670 shares
CY2023 trda Stock Issued During Period Shares Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions
14745 shares
CY2023Q4 trda Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Nonvested Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount
100000 usd
CY2024Q3 trda Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Nonvested Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount
100000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5414360 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
679625 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.12
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
260271 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.50
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
331629 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
14.32
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5502085 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.81
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3602710 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.55
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1900000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-17400000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2700000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-14032000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
35461000 usd
us-gaap Net Income Loss
NetIncomeLoss
64495000 usd
us-gaap Net Income Loss
NetIncomeLoss
2859000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40629602 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33281287 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36118930 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32942958 shares
CY2024Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1494164 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1464556 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1346453 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40629602 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34775451 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37583486 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34289411 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7959863 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3492264 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3561575 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3621505 shares
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001689375-24-000063-index-headers.html Edgar Link pending
0001689375-24-000063-index.html Edgar Link pending
0001689375-24-000063.txt Edgar Link pending
0001689375-24-000063-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
trda-20240930.htm Edgar Link pending
trda-20240930.xsd Edgar Link pending
trda-20240930x10qex311.htm Edgar Link pending
trda-20240930x10qex312.htm Edgar Link pending
trda-20240930x10qex321.htm Edgar Link pending
trda-20240930_cal.xml Edgar Link unprocessable
trda-20240930_def.xml Edgar Link unprocessable
trda-20240930_lab.xml Edgar Link unprocessable
trda-20240930_pre.xml Edgar Link unprocessable
trda-20240930_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable